WEBULL

Baxter International Inc.'s (NYSE:BAX) Shares Lagging The Industry But So Is The Business

Simply Wall St · 06/21 13:14

You may think that with a price-to-sales (or "P/S") ratio of 1.4x Baxter International Inc. (NYSE:BAX) is a stock worth checking out, seeing as almost half of all the Medical Equipment companies in the United States have P/S ratios greater than 2.6x and even P/S higher than 7x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

View our latest analysis for Baxter International

ps-multiple-vs-industry
NYSE:BAX Price to Sales Ratio vs Industry June 21st 2025

How Has Baxter International Performed Recently?

Baxter International certainly has been doing a good job lately as it's been growing revenue more than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If the company manages to stay the course, then investors should be rewarded with a share price that matches its revenue figures.

Keen to find out how analysts think Baxter International's future stacks up against the industry? In that case, our free report is a great place to start.

How Is Baxter International's Revenue Growth Trending?

The only time you'd be truly comfortable seeing a P/S as low as Baxter International's is when the company's growth is on track to lag the industry.

Retrospectively, the last year delivered an exceptional 15% gain to the company's top line. However, this wasn't enough as the latest three year period has seen the company endure a nasty 20% drop in revenue in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.

Turning to the outlook, the next three years should generate growth of 5.2% each year as estimated by the analysts watching the company. With the industry predicted to deliver 10% growth per year, the company is positioned for a weaker revenue result.

In light of this, it's understandable that Baxter International's P/S sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

What Does Baxter International's P/S Mean For Investors?

We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

We've established that Baxter International maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Plus, you should also learn about these 2 warning signs we've spotted with Baxter International.

If these risks are making you reconsider your opinion on Baxter International, explore our interactive list of high quality stocks to get an idea of what else is out there.